| Epidemiology, Prevalence and Incidence in Wet-Form (Neovascular) Age-Related Macular Degeneration | Ayşe Gül KOÇAK ALTINTAŞ | 161–166 |
| Risk Factors and Genetics in Wet-Form (Neovascular) Age-Related Macular Degeneration | EBRU NEVİN ÇETİN,GÖKHAN OZAN ÇETİN | 167–172 |
| Pathogenesis in Wet-Form (Neovascular) Age-Related Macular Degeneration | Mehmet ÖNEN | 173–177 |
| Classification and Diagnosis in Wet-Form (Neovascular) Age-Related Macular Degeneration | Işıl SAYMAN MUSLUBAŞ,Serra ARF,Murat KARAÇORLU | 178–183 |
| Laser Treatment, Photodynamic Therapy and Radiation Therapy in Wet-Form (Neovascular) Age-Related Macular Degeneration | Fatih Çakır GÜNDOĞAN | 184–188 |
| Intravitreal Ranibizumab Treatment and Treatment Regimens in Wet-Form (Neovascular) Age-Related Macular Degeneration | Murat KARAÇORLU,Işıl SAYMAN MUSLUBAŞ | 189–197 |
| Aflibercept Treatment and Treatment Algorithms in Wet-Form (Neovascular) Age-Related Macular Degeneration | MEHMET ÇITIRIK,Çağrı İLHAN,MEHMET YASİN TEKE | 198–205 |
| Intravitreal Bevacizumab Treatment in Wet-Form (Neovascular) Age-Related Macular Degeneration | Burak ERDEN,Selim BÖLÜKBAŞI,MUSTAFA NURİ ELÇİOĞLU | 206–212 |
| Steroid Therapy in Wet-Form (Neovascular) Age-Related Macular Degeneration | Şehnaz ÖZÇALIŞKAN,MEHMET ÇITIRIK | 213–218 |
| Non-Response to Anti-VEGF in Patients with Wet-Form (Neovascular) Age- Related Macular Degeneration, Treatment Resistance and Switch of Anti-VEGF Agents | Şengül ÖZDEK,Emine Esra KARACA | 219–228 |
| Surgical Treatment in Wet-Form (Neovascular) Age-Related Macular Degeneration | Coşar BATMAN,Feyza ÇALIŞ | 229–234 |
| Emerging Therapies for Wet-Form (Neovascular) Age-Related Macular Degeneration | Şaban GÖNÜL | 235–240 |
| Stem Cell and Gene Therapy For Wet-Form (Neovascular) Age-Related Macular Degeneration | Emrullah BEYAZYILDIZ,Nurullah KOÇAK |